Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM ESTCompany ParticipantsAngela Wirick - Chief Financial ...

In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...

Doctors have always told patients with atrial fibrillation (AF) to limit caffeine, saying it could trigger irregular heartbeats, however, a new international trial shows that moderate coffee intake is ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim ...

Modern semiconductor chip design faces growing complexity due to numerous timing scenarios driven by varying operating ...

Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.

Stacking dies introduces layers of complexity driven by multi-physics interactions, which must be addressed at the start of ...

Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...